The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study to assess vismodegib in the neoadjuvant treatment of locally advanced basal cell carcinoma (laBCC): The Vismodegib Neoadjuvant (VISMONEO) study.
Laurent Mortier
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Roche
Philippe Saiag
Consultant or Advisory Role - Roche
Marie Thérèse Leccia
Research Funding - Roche
Abdelkader Mahmoudi
Employment or Leadership Position - Roche
Liubinka Mirakovska
No relevant relationships to disclose
Damia Meddour
No relevant relationships to disclose
Alain Duhamel
No relevant relationships to disclose
Xavier Mirabel
No relevant relationships to disclose
Pierre Guerreschi
No relevant relationships to disclose